Cardinal Health's Disposable Instant Cold Pack is a single-use medical accessory designed for clinics, athletic trainers, and home users requiring immediate cold therapy without refrigeration. The product utilizes an endothermic reaction involving ammonium nitrate to generate cold within seconds of activation, offering a practical solution for minor sprains and bruises in emergency rooms, sports medicine settings, and households where traditional ice is unavailable.
The pack is latex-free and shelf-stable, allowing storage at room temperature which simplifies logistics for facilities with limited freezer capacity. It fits into Cardinal Health's broader Medical segment strategy of supplying branded consumables to over 90% of US hospitals. While a small-ticket item, it supports the company's ecosystem by keeping buyers within its supply chain alongside pharmaceuticals and surgical gloves.
Industry analysis projects the global hot and cold packs market to reach approximately $2.1 billion by 2033, driven by aging populations and robust sports participation. Cardinal Health recently raised its fiscal 2026 non-GAAP earnings guidance, implying around 30% year-on-year growth, reflecting strength in both its Pharmaceutical and Medical segments. The company's shares have been outperforming the broader healthcare sector following this outlook lift.
🧊 Instant cold packs activate without refrigeration for single-use therapy.
🏥 Distributed via network supplying over 90% of US hospitals.
📈 Fiscal 2026 earnings guidance implies approximately 30% growth.
💰 Global market projected to reach $2.1 billion by 2033.
📉 Shares outperform sector after EPS outlook lift.
🧊 Cardinal Health's Disposable Instant Cold Pack delivers localized cold therapy within seconds of activation without requiring refrigeration.
🏥 The product is distributed through Cardinal Health's logistics network, which supplies pharmaceuticals and medical-surgical products to more than 90% of US hospitals.
📈 Cardinal Health recently raised its fiscal 2026 non-GAAP earnings guidance to a range implying approximately 30% year-on-year growth.
🔬 The pack is latex-free and shelf-stable, designed for single-use applications in emergency rooms, athletic training, and home first-aid kits.
💰 Market research projects the global hot and cold packs market will reach about $2.1 billion by 2033 from $1.3 billion in 2026.
📉 Cardinal Health shares have been outperforming the broader healthcare sector following a recent lift in its EPS outlook.
Shares outperforming broader healthcare sector after outlook adjustment.
Global market projected to grow from $1.3B in 2026 to $2.1B by 2033.
Supplies products to over 90% of US hospitals.
Bullish Signals
Cardinal Health recently raised its fiscal 2026 non-GAAP earnings guidance, implying around 30% year-on-year growth driven by strength in both Pharmaceutical and Medical segments.
The company's shares have been outperforming the broader healthcare sector following the positive adjustment to its earnings outlook.
The global hot and cold packs market is projected to grow significantly from $1.3 billion in 2026 to approximately $2.1 billion by 2033 due to aging populations and sustained sports participation.
Cardinal Health's logistics network supplies products to over 90% of US hospitals, providing a robust distribution channel for its consumable portfolio.
Cardinal Health (CAH) recently traded at $212.79 per share, reflecting a 4.1% gain during the evening session and a year-over-year return of 33.6%, outperforming the S&P 500 by 10.9%. The company operates as a healthcare services and products provider with over 53,000 employees, offering a 1.0% dividend yield over the last 12 months. While Cardinal Health demonstrates growing revenues, positive EPS growth, healthy leverage, and generally positive cash flows, it faces challenges including slimmer gross margins than peers and a current ratio of 0.91, indicating insufficient current assets to cover current liabilities.
Valuation metrics show a trailing twelve-month P/E ratio of 30.9 versus a sector average of 22.94, with a forward P/E of 16.9 based on EPS guidance of $11.98. The PEG ratio stands at 2.48, suggesting the stock may be overvalued relative to its growth rate. Analyst consensus remains positive with an average buy rating and target prices ranging from $215.00 to $275.00, averaging $245.27 per share. Institutional ownership is high at 89.9%, led by Blackrock Inc. with a 12% stake, while insider ownership is minimal at 0.26%. The article concludes with standard disclaimers regarding educational purposes and market sentiment analysis for other tickers like COIN, LKNCY, and VIZIO, which are unrelated to Cardinal Health's fundamentals.
📈 Shares rose 4.1% to $212.79, up 33.6% year-over-year.
⚠️ Current ratio of 0.91 signals insufficient liquidity for liabilities.
💰 Analysts rate it "Buy" with a target price of $245.27.
📈 Cardinal Health shares rose 4.1% in today's evening session, trading at $212.79 per share.
📊 The stock gained 33.6% over the last year, outperforming the S&P 500 by 10.9%.
🏢 Cardinal Health operates as a large-cap healthcare services and products company based in Dublin, Ohio.
👥 The company employs 53,084 full-time workers across the United States and internationally.
💰 Cardinal Health has provided a dividend yield of 1.0% over the past 12 months.
⚠️ Despite positive cash flows and leverage, the firm's current ratio is 0.91, indicating insufficient current assets to cover liabilities.
📉 Gross margins for Cardinal Health are slimmer than those of its industry peers.
📊 The trailing twelve-month P/E ratio stands at 30.9, which is higher than the sector average of 22.94.
🔮 Based on EPS guidance of $11.98, the forward P/E ratio is calculated at 16.9.
📉 A PEG ratio of 2.48 suggests that the company's shares may be overvalued relative to growth rates.
👍 Analysts maintain an average "Buy" rating with a consensus target price of $245.27 per share.
🎯 Target prices from analysts range between $215.0 and $275.0 per share.
📉 Short interest is low at 3.7% of the company's total shares outstanding.
🏛️ Institutional investors own 89.9% of Cardinal Health's shares, while insider ownership is minimal at 0.26%.
🖤 BlackRock Inc. holds the largest stake with 12% of shares worth approximately $6.06 billion.
⚠️ The analysis includes a disclaimer that past performance and data are not reliable indicators of future price movements.
📉 Market Inference does not provide financial advice or recommend buying or selling any specific security.
Bullish Signals
Cardinal Health gained 33.6% last year, beating S&P 500 by 10.9%.
Revenues and reinvestment are growing with positive EPS growth.
Financials show positive cash flows and healthy leverage levels.
Analysts target $245.27, offering upside from current price of $212.79.
Stock rated 'Buy' with forward P/E of 16.9 on $11.98 EPS.
Risk Factors
Current ratio of 0.91 indicates insufficient liquidity to cover liabilities.
Bullish Signals
Cardinal Health returned gains of 33.6% last year, significantly outperforming the S&P 500 index by 10.9%.
The company is experiencing growing revenues and increasing reinvestment in its business alongside positive EPS growth.
Financial statements display generally positive cash flows and healthy leverage levels.
Analysts have set an average target price of $245.27 per share, representing upside potential from the current trading price of $212.79.
The stock carries an average analyst rating of 'Buy' with a forward P/E ratio of 16.9 based on EPS guidance of $11.98.
Risk Factors
The company's current ratio is 0.91, meaning it does not have enough current assets to cover its current liabilities, which raises liquidity concerns.
Cardinal Health (CAH) shares have outperformed the broader market and industry peers, losing only 2.5% year-to-date compared to a 9.3% decline in the healthcare industry and an 8.1% rise in the S&P 500. The company reported strong fiscal third-quarter results driven by robust demand in pharmaceutical distribution and accelerating specialty services, positioning it for continued growth through portfolio expansion. Analysts assign the stock a Zacks Rank #2 (Buy), noting its market capitalization of $46.93 billion and projecting 15.7% revenue growth over the next five years. Cardinal Health consistently surpassed earnings estimates in each of the trailing four quarters with an average surprise of 13.21%.
Core earnings momentum is driven by the Pharmaceutical and Specialty Solutions segment, which delivered 11% revenue growth and 18% profit growth in the third quarter of fiscal 2026. Specialty revenues grew more than 20%, with oncology expanding over 30%, bolstering long-term earnings potential while reducing reliance on low-margin traditional drug distribution. Management expects specialty revenues to exceed $50 billion in fiscal 2026, supported by MSO expansion, biopharma solutions, and the Solaris integration. Additionally, growth businesses such as At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics contributed significantly, with combined revenues surging 31% to $1.7 billion and profit rising 34% to $179 million.
Financial strength is underscored by robust cash flow generation, which saw adjusted free cash flow reach $1.7 billion in the third quarter, prompting a raised full-year guidance of $3.3-$3.7 billion for fiscal 2026. The company has repurchased $1 billion worth of shares year-to-date while reducing leverage to 3.0x, maintaining flexibility for specialty expansion and disciplined acquisitions. Operational execution is improving through automation, technology upgrades, and supply-chain investments that maintained record-high service levels despite winter storms and global disruptions. These initiatives aim to enhance scalability and margin resilience across the GMPD segment.
Despite these strengths, investors should note specific headwinds affecting revenue visibility. Inflation Reduction Act (IRA) pricing adjustments reduced reported pharmaceutical revenue growth by approximately 6 percentage points in the third quarter, effectively offsetting gains from GLP-1 drugs. The GMPD segment faces execution risks with flat year-over-year revenues and a profit decline to $25 million due to tariff headwinds, lower distribution volumes, and softer demand for respiratory and laboratory products. While estimate revisions have improved by 3.9% over the past 30 days to an earnings per share consensus of $10.72 for fiscal 2026, structural shifts like loss-of-exclusivity events may continue to limit top-line growth visibility even as profitability improves.
📈 Q3 revenue grew 11% driven by strong specialty and pharmaceutical demand.
💰 Adjusted free cash flow hit $1.7B with 2026 guidance raised.
🎯 Earnings beat estimates for four consecutive quarters on average.
💼 Shares outperformed the sector, down only 2.5% as competitors fell.
🚀 Specialty revenues expanded over 20% with oncology growing more than 30%.
📈 Cardinal Health delivered strong fiscal Q3 results, driven by robust pharmaceutical distribution and accelerating specialty services.
💼 The company holds a Zacks Rank #2 (Buy) status and is positioned for continued growth via its expanding specialty portfolio.
📉 Shares have lost 2.5% year-to-date compared to the industry’s 9.3% decline, while the S&P 500 rose 8.1% in the same period.
💰 Cardinal Health has a market capitalization of $46.93 billion and projects 15.7% growth over the next five years.
🎯 Earnings have surpassed the Zacks Consensus Estimate for four consecutive quarters with an average surprise of 13.21%.
🚀 Pharmaceutical and Specialty Solutions segment revenue grew 11% in Q3 fiscal 2026, fueled by strong demand across specialty, generics, and consumer health.
⚡ Specialty revenues expanded over 20%, with oncology growing more than 30%, while management expects specialty revenues to exceed $50 billion in fiscal 2026.
🌐 At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics saw revenues surge 31% to $1.7 billion in the fiscal third quarter.
🩺 Theranostics growth exceeded 30%, while Advanced Diabetes Supply added nearly 500,000 patients through continued integration progress.
💵 The company generated $1.7 billion in adjusted free cash flow in the third quarter and raised fiscal 2026 guidance to $3.3-$3.7 billion.
🔄 Cardinal Health repurchased $1 billion worth of shares year-to-date, reducing leverage to 3.0x within its target range.
📉 The Inflation Reduction Act (IRA) pricing adjustments reduced reported revenue growth by approximately 6 percentage points in the fiscal third quarter.
🏭 Global Medical Products and Distribution (“GMPD”) segment revenues were flat year-over-year due to tariff-related headwinds and lower distribution volumes.
🛠️ Management continues to invest in automation, technology upgrades, and supply-chain improvements to maintain record-high service levels.
📊 The Zacks Consensus Estimate for 2026 EPS improved 3.9% over the past 30 days to $10.72.
Repurchased $1B shares YTD; reduced leverage to 3.0x within target range.
Earnings exceeded Zacks consensus for 4 quarters with +13.21% average surprise.
Shares down only 2.5% vs industry's 9.3% decline this year.
Specialty revenues projected >$50B in fiscal 2026 via expansion and Solaris integration.
EPS estimate improved 3.9% to $10.72 over past 30 days.
Bullish Signals
Cardinal Health delivered strong fiscal third-quarter results with revenue growth in its Pharmaceutical and Specialty Solutions segment of 11%, including specialty revenues growing over 20%.
Oncology growth within the pharmaceutical segment expanded by more than 30%, while theranostics grew by over 30% in other businesses like Nuclear and Precision Health Solutions (NPHS).
The company generated $1.7 billion in adjusted free cash flow during the third quarter and has raised its fiscal 2026 free cash flow guidance to $3.3-$3.7 billion.
Cardinal Health repurchased $1 billion worth of shares year to date, exceeding its baseline target while reducing leverage to 3.0x, which is comfortably within its target range.
Management increased fiscal 2026 free cash flow guidance to $3.3-$3.7 billion, reflecting confidence in future performance and continued improvement in the business.
Earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 13.21%.
The company's shares have lost only 2.5% so far this year compared to the industry's 9.3% decline, demonstrating relative strength in a challenging environment.
Specialty revenues are expected to exceed $50 billion in fiscal 2026, supported by MSO expansion, biopharma solutions, and the Solaris integration.
The Zacks Consensus Estimate for earnings per share (EPS) has improved 3.9% to $10.72 over the past 30 days, indicating an improving estimate revision trend.
Risk Factors
Cardinal Health's shares have lost 2.5% year-to-date, significantly underperforming the S&P 500 which increased 8.1% during the same period.
The Global Medical Products and Distribution (GMPD) segment revenues remained flat year over year while profit declined to $25 million due to tariff-related headwinds and lower distribution volumes.
Inflation Reduction Act (IRA)-related WAC pricing adjustments reduced revenue growth by approximately 6 percentage points in the fiscal third quarter, offsetting positive GLP-1 contributions.
GMPD profitability remains vulnerable to external pressures such as tariffs, fuel costs, and commodity inflation, which could delay margin recovery in this segment.
Lower branded drug prices can suppress reported top-line growth due to IRA pricing changes, even if contract economics remain protected through fee renegotiations.
The shift from branded drugs to generics following loss-of-exclusivity events can limit revenue visibility despite being favorable for profitability.
Cardinal Health is positioning itself as a foundational element of the U.S. healthcare infrastructure by leveraging its scale and operational reliability across pharmaceutical distribution, specialty care, and advanced logistics. The company's Pharmaceutical & Specialty Solutions segment contributed approximately $61 billion to quarterly revenues, supporting tens of thousands of healthcare locations including hospitals, pharmacies, and clinics. Beyond traditional distribution, Cardinal Health has expanded into specialty drug distribution, physician-facing MSO platforms, biopharma services, logistics, nuclear medicine, and precision health solutions through its Specialty Alliance networks and Sonexus hub services. Management emphasizes the company's ability to maintain service continuity during supply-chain disruptions, with a majority of manufacturing facilities based in the United States, reinforcing its role as a trusted intermediary. The company is driving integration across healthcare supply chains through its "specialty flywheel" strategy, which connects manufacturers, providers, and patients to enhance visibility and efficiency.
From a valuation perspective, Cardinal Health shares have lost 2.8% so far this year compared with the industry's 10.3% decline. The stock trades at a forward price-to-earnings ratio of 16.93, which is above the industry average and higher than its five-year median of 13.67. It carries a Value Score of A, and the Zacks Consensus Estimate for fiscal 2026 earnings implies a 30.1% rise from the year-ago period's level. The stock currently carries a Zacks Rank #2 (Buy). Management commentary in the third quarter of fiscal 2026 suggests the company is evolving beyond a distributor into a critical healthcare infrastructure partner, with scale and ecosystem integration reinforcing its long-term relevance.
💊 Cardinal Health generated $61B quarterly revenue with strong U.S. manufacturing reliability.
🚀 CAH shares dropped only 2.8% this year versus the industry's 10.3% decline.
🤖 Hims & Hers serves 2.6M subscribers via an AI-enabled consumer-first platform.
🏥 LifeMD integrates telehealth, pharmacy, and diagnostics into a unified virtual care ecosystem.
📈 Zacks ranks CAH as a Buy with estimated 2026 earnings up 30.1%.
🏥 Cardinal Health is positioning itself as a foundational layer of the U.S. healthcare system by leveraging scale and operational reliability.
💊 The company's Pharmaceutical & Specialty Solutions segment contributed approximately $61 billion to quarterly revenues.
🌐 Cardinal Health's influence spans multiple layers including specialty drug distribution, MSO platforms, biopharma services, and nuclear medicine.
🤝 Specialty Alliance networks in oncology, rheumatology, and urology deepen provider relationships with the company.
🏭 The majority of Cardinal Health's manufacturing facilities are based in the United States to reinforce supply chain reliability.
🔄 Cardinal Health is driving integration across healthcare supply chains through its "specialty flywheel" strategy connecting manufacturers, providers, and patients.
📉 CAH shares have lost 2.8% so far this year compared with the industry's 10.3% decline.
📊 Cardinal Health trades at a forward price-to-earnings ratio of 16.93, which is above the industry average.
🚀 The Zacks Consensus Estimate for fiscal 2026 earnings implies a 30.1% rise from the year-ago period's level.
📈 The stock currently carries a Zacks Rank #2 (Buy).
🤖 Hims & Hers Health is reshaping infrastructure by building a consumer-first, technology-enabled care platform bypassing traditional friction points.
👥 Hims & Hers now supports nearly 2.6 million subscribers and tens of millions of annual patient touchpoints using AI.
🏥 LifeMD is redefining healthcare infrastructure by creating an integrated virtual care ecosystem combining telehealth, pharmacy, diagnostics, and insurance integration.
🤖 LifeMD uses AI to improve provider productivity and personalize treatment across weight management and chronic care.
📜 This article originally published on Zacks Investment Research (zacks.com).
Bullish Signals
Cardinal Health evolves into critical healthcare infrastructure partner leveraging scale.
$61B quarterly revenue from Pharmaceutical & Specialty Solutions segment.
Expanded into specialty drug distribution and precision health solutions.
Maintains service continuity during supply-chain disruptions with US manufacturing.
Specialty flywheel strategy connects manufacturers, providers, and patients.
Shares lost only 2.8% vs industry's 10.3% decline.
Fiscal 2026 earnings imply 30.1% rise from year-ago level.
Value Score A with forward P/E of 16.93.
Risk Factors
Shares underperformed healthcare sector with only 2.8% drop vs 10.3% industry decline.
Forward P/E of 16.93 exceeds industry average and five-year median of 13.67.
High valuation contradicts A Value Score suggesting potential overvaluation relative to peers.
Bullish Signals
Cardinal Health is evolving from a distributor into a critical healthcare infrastructure partner, leveraging scale and operational reliability to deepen its role across pharmaceutical distribution, specialty care, and advanced logistics.
The company's Pharmaceutical & Specialty Solutions segment contributed approximately $61 billion to quarterly revenues, underscoring the massive scale and centrality of its operations to healthcare delivery.
Cardinal Health has expanded into high-value areas including specialty drug distribution, physician-facing MSO platforms, biopharma services, logistics, nuclear medicine, and precision health solutions.
Management emphasizes Cardinal Health's ability to maintain service continuity during industry-wide supply-chain disruptions and drug shortages, with the majority of its manufacturing facilities based in the United States.
The company's 'specialty flywheel' strategy connects manufacturers, providers, and patients through a unified ecosystem, enhancing visibility, improving efficiency, and creating cross-segment growth opportunities.
Shares of CAH have lost only 2.8% so far this year compared with the industry's 10.3% decline, demonstrating relative outperformance during market downturns.
The Zacks Consensus Estimate for Cardinal Health's fiscal 2026 earnings implies a 30.1% rise from the year-ago period's level, signaling strong growth expectations.
Cardinal Health carries a Value Score of A and trades at a forward price-to-earnings ratio of 16.93, which is above the industry average but supported by its strategic positioning.
Risk Factors
Shares of Cardinal Health (CAH) have underperformed the broader healthcare industry this year, declining only 2.8% compared to the industry's 10.3% drop.
The stock trades at a forward price-to-earnings ratio of 16.93, which is significantly above both the industry average and its own five-year median of 13.67.
Despite the high valuation, CAH carries a Value Score of A, suggesting potential overvaluation relative to peers.
Cardinal Health Inc. (CAH) recently announced a strategic combination of financial improvements, raising its quarterly dividend and lifting fiscal 2026 earnings guidance in early May 2026. This move signals management's confidence in the momentum within its specialty pharmaceutical business and core distribution operations. The company extended its impressive streak of annual dividend growth to 29 consecutive years as of early April 2026, with the most recent specific increase being approximately $0.0051 per share announced on May 5, 2026.
The updated outlook is centered on improved non-GAAP earnings guidance for fiscal 2026, with management projecting a range between $10.70 and $10.80 per share, representing a midpoint increase of roughly $0.50 compared to previous estimates. This guidance reflects strong performance expectations despite the typical low-margin nature of the distributor business, which relies on high volumes of branded and generic pharmaceuticals as well as medical and surgical products. The company serves hospitals, pharmacies, and care providers across the United States, with a significant portion of its revenue driven by specialty distribution, particularly in oncology and complex therapies where demand for advanced treatments is rising.
Financially, Cardinal Health currently pays an annualized dividend of about $2.04 per share, which translates to a yield of approximately 1.05% based on recent trading levels. The payout ratio stands at roughly 31% of trailing earnings and is estimated between 17% and 19% when looking at current and next-year earnings, as well as around 17% of operating cash flow. These metrics suggest a conservative approach where the company retains the majority of its earnings to reinvest in operations, reduce debt, or fund other corporate priorities while maintaining safety for income-oriented investors.
The long-term dividend growth rate over the past five years has averaged about 1.02% per year, reflecting a cautious expansion strategy that balances payout increases with ongoing margin pressure and necessary investments in technology and specialty services. For US investors, the recent incremental hike is viewed as a positive sign of management's willingness to sustain the pattern of annual increases even within a competitive distribution environment characterized by high volumes but relatively thin margins.
📈 Cardinal Health raised its 2026 earnings guidance to $10.70–$10.80 EPS.
💰 Dividend increases 29 consecutive years; annualized payout is now ~$2.04/share.
🏥 Business relies on high-volume drug distribution and growing specialty therapeutics.
📈 Cardinal Health raised its quarterly dividend and lifted fiscal 2026 earnings guidance to signal confidence in its business momentum.
💰 The most recent dividend adjustment added approximately $0.0051 per share, extending the company's streak of annual increases to 29 consecutive years.
📊 Management now projects non-GAAP earnings per share for fiscal 2026 in a range of roughly $10.70 to $10.80, representing a significant upward revision.
🏥 Cardinal Health operates as one of the largest healthcare distributors in the US, supplying prescription drugs, OTC medicines, and medical products to hospitals and pharmacies.
💊 The company’s revenue model relies on high volumes of branded and generic pharmaceuticals with additional contributions from specialty drug services and medical products.
🦠 Specialty distribution, particularly in oncology and complex therapies, has become an increasingly important growth driver as advanced treatments take a larger share of drug spending.
🔬 Beyond pharmaceuticals, Cardinal Health generates meaningful revenue from medical and surgical products such as gloves, gowns, needles, and lab equipment used in hospitals.
📦 The firm has invested in value-added services like inventory management and analytics to deepen customer relationships and support margins despite competitive pricing pressures.
💵 As of early April 2026, Cardinal Health pays an annualized dividend of about $2.04 per share, corresponding to a yield of roughly 1.05%.
📉 The dividend payout ratio stands at approximately 31% of trailing earnings and around 17-19% based on current and next-year earnings estimates.
⏳ Over the past five years, Cardinal Health’s dividend has grown by about 1.02% per year on average, reflecting a cautious approach to increasing payouts.
📈 The updated fiscal 2026 guidance indicates stronger than previously expected earnings momentum driven by both distribution and specialty segments.
💼 Analysts and investors are closely monitoring how the updated outlook shapes the stock’s medium-term profile and validates management's strategic priorities.
Bullish Signals
Cardinal Health Inc. raised dividend and lifted fiscal 2026 guidance.
Company extends impressive streak of raising dividends for 29 consecutive years.
Management raised non-GAAP EPS guidance range to $10.70-$10.80 for FY2026.
Conservative payout ratio of roughly 31% ensures high dividend growth safety.
Specialty pharma distribution remains a key driver with rising advanced demand.
Risk Factors
Low margins make earnings sensitive to volume or pricing shifts.
Revenue depends heavily on large, competitive customer contracts.
Medical segment vulnerable to hospital spending and supply chain trends.
Limited upside with non-GAAP EPS projection between $10.70-$10.80.
Low dividend growth of ~1.02% annually lags investor expectations.
High retention rates limit immediate yield appeal despite increases.
Focus on specialty pharma exposes company to higher therapy risks.
Bullish Signals
Cardinal Health Inc. announced a quarterly dividend increase and lifted its fiscal 2026 earnings guidance, signaling strong confidence in its specialty pharmaceutical and distribution franchises.
The company extended its impressive streak of raising dividends for 29 consecutive years as of early April 2026, reinforcing its status as a reliable income investment for shareholders.
Management raised its non-GAAP earnings per share guidance for fiscal 2026 to a range of $10.70 to $10.80, representing a positive midpoint increase of approximately $0.50 compared to previous targets.
Cardinal Health maintains a conservative dividend payout ratio of roughly 31% based on trailing earnings and an even lower multiple of 17% to 19% against current and next-year estimates, providing high safety for dividend growth.
The company's specialty pharmaceutical distribution segment, including oncology and complex therapies, continues to serve as a key growth driver supported by rising demand for advanced treatments.
Management's recent investments in value-added services like inventory management and analytics are positioned to deepen customer relationships and potentially support margin expansion.
Risk Factors
Cardinal Health operates on a business model characterized by high volumes and relatively low margins, making earnings highly sensitive to even small shifts in volume or pricing.
Revenue depends heavily on the flow of branded and generic pharmaceuticals, meaning individual customer contracts are large and inherently competitive.
The medical segment performance is vulnerable to fluctuations in hospital spending trends, procedure volumes, and supply-chain dynamics as providers adjust inventories.
While management raised guidance for fiscal 2026, non-GAAP earnings per share projections range only between $10.70 and $10.80, indicating limited upside potential from this revision.
The company's average dividend growth over the past five years is low at approximately 1.02% annually, reflecting a cautious approach that may lag investor expectations for capital returns.
A significant portion of earnings (roughly 69%) and operating cash flow (around 81-83%) are retained rather than paid out as dividends, which limits immediate yield appeal despite the streak of increases.
Specialty pharmaceutical distribution is becoming increasingly important for growth, but this focus exposes the company to higher risks associated with high-value therapies and shifting drug spending patterns.
The article evaluates Cardinal Health (CAH) and UnitedHealth Group (UNH) over a 12-month period starting May 29, 2025, comparing their performance against an earlier prediction that favored Cardinal Health. Although Cardinal Health was the initial recommendation, UnitedHealth outperformed in terms of total return, rising from $296.80 to $401.16 for a gain of 35.2% by May 11, 2026, compared to Cardinal Health's 21.8% return which moved from $153.00 to $186.35. The analysis attributes UnitedHealth's stronger recent performance to its recovery under CEO Stephen Hemsley, noting a significant 27.0% gain in the past month driven by a Q1 2026 adjusted earnings beat where actual results of $7.23 exceeded the consensus estimate of $6.61.
Recent financial data highlights divergent paths for the two healthcare giants; UnitedHealth improved its medical cost ratio by 90 basis points to 83.9%, while Cardinal Health faced a market downturn despite a non-GAAP earnings beat in Q3 FY26. The issues impacting Cardinal Health included a 2.09% revenue miss, a 30.27% year-over-year decline in operating income, and a $184 million goodwill impairment related to Navista and ION, leading to a 6.6% decline year-to-date. In contrast, UnitedHealth's upside potential has been partially consumed by its rally, though it remains supported by strong cash generation with $2.0 billion in dividends paid out alone in Q1 2026.
Looking forward, the article notes that Cardinal Health currently offers a more bullish analyst outlook than UnitedHealth, which trades above its consensus target price. Wall Street analysts project a consensus target for Cardinal Health of $245.27, implying substantial upside, alongside an 88% bullish rating distribution. Management at Cardinal has raised full-year FY26 non-GAAP earnings guidance to between $10.70 and $10.80, representing 30% to 31% growth. Conversely, UnitedHealth carries lingering risks such as Department of Justice inquiries regarding Medicare and a decline in its member count for Medicare Advantage plans, which keeps the stock trading near its consensus target despite a still-positive 82% analyst sentiment.
The summary concludes that investment choice depends on the investor's profile and risk tolerance; UnitedHealth is positioned for retirement portfolios seeking stable dividends and proven turnaround results with lower volatility relative to the sector, whereas Cardinal Health suits investors with a longer horizon seeking higher upside potential based on wider analyst price targets and faster projected earnings growth. The article suggests that on a risk-adjusted basis, Cardinal Health currently presents a favorable setup given UnitedHealth has completed much of its rebound while Cardinal retains significant growth potential ahead.
📉 UnitedHealth recently outperformed Cardinal Health with 35.2% returns vs 21.8%.
⚠️ Cardinal Health faces short-term momentum issues despite a revised upside target.
💡 Investment choice now hinges on investor profile, balancing growth versus dividends.
📉 The original recommendation favoring Cardinal Health over UnitedHealth was proven incorrect as UnitedHealth significantly outperformed Cardinal in the trailing 12 months.
💰 UnitedHealth returned 35.2% between May 2025 and May 2026, while Cardinal Health returned 21.8% during the same period.
📊 UnitedHealth's strong recent performance was driven by a Q1 2026 EPS beat of $7.23 versus the $6.61 consensus estimate.
⚖️ Cardinal Health delivered a Q3 FY26 non-GAAP EPS beat but suffered from a revenue miss and a significant goodwill impairment charge.
📉 Short-term momentum has shifted against Cardinal, which is down 10.7% over the past month despite missing on key growth metrics.
💡 Analyst consensus for UnitedHealth suggests less upside potential at $387.27 compared to its current share price, reflecting a completed rebound.
🔼 Analyst sentiment favors Cardinal Health with a Wall Street target of $245.27 and an 88% bullish rating distribution from coverage.
📈 Cardinal Health has raised its full-year 2026 EPS guidance to between $10.70 and $10.80, representing 30% to 31% growth.
🧘♂️ UnitedHealth's turnaround under CEO Stephen Hemsley has been validated by improved medical cost ratios and stronger operational metrics.
⚠️ Long-term concerns persist for UnitedHealth regarding a DOJ probe and a decline in Medicare Advantage membership of 965,000 members.
🛡️ Cardinal Health offers higher beta with lower volatility (0.54), making it potentially attractive for investors seeking near-term drawdown tolerance.
💵 UnitedHealth generated substantial dividend income by paying $2.0 billion in Q1 2026 alone, appealing to retirement-focused investors.
🎯 Risk-adjusted analysis currently favors Cardinal Health due to wider implied upside and faster growth guidance despite UnitedHealth's strong recent rally.
🔄 The article concludes that the investment decision now splits based on investor profile, with UnitedHealth suited for scale and dividends.
Bullish Signals
Cardinal Health delivered strong total returns of 21.8%.
Q3 FY26 EPS beat guidance with 30-31% growth raised.
Wall Street consensus target implies material upside at $245.27.
88% bullish coverage with no Sells and three Strong Buys.
Beta of 0.54 offers lower volatility than peers.
Risk Factors
Stock price doubled since May, leaving little upside.
Overhangs include DOJ Medicare actions and 965k membership drop.
Rally consumed value cushion for waiting investors.
Q1 FY2026 EPS beat $7.23 limits future upside.
Cardinal Health income fell 30.27% with $184m impairment.
Bullish Signals
Cardinal Health delivered strong total returns of 21.8% over the past year, growing from $153.00 to $186.35.
Following a Q3 FY26 non-GAAP EPS beat of $3.17 against estimates of $2.79, management has raised full-year guidance to reflect 30% to 31% growth in non-GAAP EPS.
The Wall Street consensus price target of $245.27 implies material upside for the stock.
Analyst sentiment remains robust with 88% bullish coverage, consisting of three Strong Buy ratings and twelve Buy ratings versus zero Sells.
With a beta of 0.54, Cardinal Health offers lower volatility compared to peers while maintaining exposure to healthcare growth.
The stock is currently trading below the analyst consensus target, providing room for price appreciation toward $231.18 according to 24/7 Factor targets.
Risk Factors
UnitedHealth Group's stock price has nearly doubled since May 29, 2025, leaving very little room for further appreciation as the current share price is already above Wall Street consensus targets.
UnitedHealth faces significant overhangs from ongoing Department of Justice Medicare actions and a recent decline in its Medicare Advantage membership of 965,000 members.
The stock has rallied significantly, eating up much of the cushion for investors who were previously buying on value or waiting for a better entry point.
UnitedHealth's Q1 FY2026 adjusted EPS of $7.23 beat consensus estimates, which is often interpreted by markets as limited upside potential once strong results are priced in.
Cardinal Health recently reported a 30.27% year-over-year operating income decline and took an $184 million goodwill impairment related to Navista and ION.
Cardinal Health, Inc. (CAH) presented at the Bank of America Global Healthcare Conference on May 13, 2026, with CFO Aaron Alt and VP of Investor Relations Dave Frost discussing recent performance and strategic outlook. During the opening remarks, Alt highlighted that the company had recently released Q3 earnings, which showed strong results across its enterprise. Specifically, the Pharma business achieved an 18% profit growth, while the 'Other' segment, comprised of three growth businesses, saw profit growth exceeding 30%. Management emphasized their continued execution on the GMPD (Greater Medication Profitability and Distribution) improvement plan, which is central to their overall operational efforts. The conference call was initiated by Allen Lutz from BofA Securities, who introduced the executives for a Q&A session, though specific details of the questions and answers were not included in the provided text.
The presentation focuses on capitalizing on recent profitability gains and maintaining momentum through strategic initiatives like the GMPD plan. With earnings released only days prior, the company leveraged these positive figures to frame its current market position. The transcript captures the initial sentiment from management, indicating confidence in their diversified revenue streams within the healthcare distribution sector. While deeper financial metrics or specific guidance for future quarters are not visible in this excerpt, the emphasis on double-digit profit growth in key segments suggests a robust operational trajectory that investors likely scrutinized during the conference session.
💼 Executives presented at BofA conference on May 13, 2026.
✅ Q3 earnings showed strong performance across the enterprise.
📈 Pharma segment profits grew 18%, while others exceeded 30%.
🚀 Management remains confident in executing their GMPD improvement plan.
📅 Cardinal Health presented at the Bank of America Global Healthcare Conference on May 13, 2026.
💼 The company's executive team includes CFO Aaron Alt and VP of Investor Relations Dave Frost.
⚠️ Management issued standard forward-looking statements subject to risks detailed in SEC filings.
✅ The company recently released Q3 earnings results that they consider strong across the enterprise.
📈 Pharma business segment delivered 18% profit growth in the third quarter.
🧬 The "other" category, consisting of three specific growth businesses, saw profit growth exceeding 30%.
🚀 Management expressed confidence in executing their GMPD improvement plan to drive overall performance.
Bullish Signals
Pharma profit grew 18%.
'3 growth businesses' profits rose over 30%.
Management reaffirmed strong GMPD execution.
Risk Factors
No specific quantitative risks or downside catalysts disclosed.
Lack of negative commentary despite recent strong earnings.
Bullish Signals
Cardinal Health's Pharma business delivered a strong 18% profit growth, demonstrating robust performance in their core pharmaceutical segment.
Their other business units, specifically referred to as the '3 growth businesses', achieved an impressive over 30% profit increase, indicating significant upside potential.
Management reaffirmed strong execution of their GMPD (Global Medicine & Patient Data) improvement plan, which is critical for driving overall enterprise growth.
Risk Factors
Management provided only a general reference to SEC filings for forward-looking statements, without specifying any specific quantitative risks or downside catalysts in this transcript.
The company noted that earnings were released just days prior and that they 'feel really good,' which may indicate the absence of negative commentary typically included when significant headwinds are present.
JPMorgan Chase recently raised its price target on Cardinal Health (NYSE:CAH) to $215 per share, reflecting continued analyst interest in the healthcare distributor's fundamentals. The article contextualizes this bullish rating against a backdrop of recent stock volatility, noting that CAH shares actually saw a 7.8% decline in the session preceding the report. This divergence between the price target hike and intraday price movement suggests investors are weighing the high valuation multiple or future expectations against short-term market fluctuations.
Fundamentally, Cardinal Health remains a dominant force in the US healthcare supply chain, holding approximately 20% market share for drug distribution and ranking second only to McKesson by revenue. The company's business is heavily skewed towards pharmaceuticals, which contribute over 75% of its total revenue through brand-name and generic channels, while its medical segment focuses on high-volume items like surgical gloves, gowns, and devices driven by post-pandemic demand. Recent fiscal year data from June 30, 2025, showed massive scale with $226.8 billion in total revenue, underlining its position as a critical logistical backbone for hospitals and pharmacies nationwide.
The article highlights that Cardinal Health's growth is tethered to the broader US healthcare market, which CMS projects will reach spending of $4.9 trillion by 2026. Despite potential margin compression from drug pricing reforms, the company benefits from volume growth and its strategic focus on specialty pharmaceuticals and home infusion services, areas aligned with an aging American demographic. Analysts like Zacks continue to endorse the stock with a 'Buy' rating (Zacks Rank #2) and an A grade for value, indicating that the broader investment community believes in the stability of the company's distribution infrastructure against volatile market conditions. The ticker remains listed on the NYSE with over 90% of its revenue generated domestically, making it a primary proxy for US pharmaceutical demand and healthcare supply chain trends.
📉 JPMorgan raised its price target to $215 despite a 7.8% same-day stock drop.
💊 Cardinal Health ranks second in US pharma distribution with massive FY2025 revenue.
🏛️ The company generates over 75% of income from pharmaceuticals and holds a 20% market share.
📈 JPMorgan Chase raised its price target for Cardinal Health (CAH) shares to $215 per share on May 11, 2026.
📉 Despite the analyst upgrade, the stock experienced a 7.8% decline in trading on that same date.
🏆 Zacks Investment Research maintains a "Buy" recommendation (Rank #2) and an "A" grade for value on Cardinal Health.
💊 Cardinal Health operates as the second-largest distributor of pharmaceuticals and medical products in the US, trailing only McKesson by revenue.
📦 In fiscal year 2025, the company reported total revenue of $226.8 billion through its Pharmaceutical and Medical segments.
💉 The Pharmaceutical segment contributes over 75% of revenue, focusing on brand-name drugs, generics, and opioids managed via OptumRx.
🩺 The Medical segment generates income from devices, apparel, surgical kits, gloves, gowns, and at-home patient solutions.
📊 Cardinal Health holds approximately 20% market share in US drug distribution, providing stability amid rising demand for pharmaceuticals.
📉 The company faces margin pressure from drug pricing reforms but expects growth driven by high volume and specialty pharma trends.
👵 Business alignment with aging demographics supports long-term relevance through specialty pharma and home infusion services.
🇺🇸 With over 90% of revenue originating from North America, the stock serves as a proxy for US healthcare spending, projected at $4.9 trillion in 2026.
🏢 Cardinal Health competes in a consolidating sector involving pharmacy benefit managers and hospital systems.
🚫 This article does not constitute investment advice, noting that stocks are volatile financial instruments.
Bullish Signals
JPMorgan raises price target to $215.
Zacks awards 'Buy' rating with 'A' value grade.
Record revenue reaches $226.8 billion for FY 2025.
Dominant #2 US position with 20% drug market share.
Sustained post-pandemic demand boosts medical segment revenue.
US healthcare spending projected to hit $4.9 trillion in 2026.
Focus on specialty pharma supports aging population trends.
Risk Factors
Cardinal Health stock fell 7.8% on May 11, 2026.
US medical sector faces margin compression from drug pricing reforms.
90%+ revenue reliance exposes company to domestic economic risks.
Bullish Signals
JPMorgan Chase & Co. raised its price target for Cardinal Health to $215, indicating strong analyst confidence in the stock's value.
Zacks awarded Cardinal Health a 'Buy' rating with Rank #2 and a Value grade of 'A', highlighting its financial strength.
The company reported record-breaking total revenue of $226.8 billion for the fiscal year ended June 30, 2025.
Cardinal Health holds a dominant #2 position in the US medical distribution sector with over 20% market share in drug distribution.
Revenue from the Medical segment is being boosted by sustained post-pandemic demand for products like gloves, gowns, and surgical kits.
US healthcare spending is projected to reach $4.9 trillion in 2026, providing a stable foundation for Cardinal Health's growth.
The company aligns well with demographic trends as its focus on specialty pharma and home infusion supports an aging US population.
Risk Factors
Cardinal Health stock declined by 7.8% during the trading session on May 11, 2026, despite a concurrent analyst price target raise.
The company operates in the US medical distribution sector which faces margin compression due to ongoing drug pricing reforms.
With only 90%+ of revenue coming from North America, Cardinal Health remains highly exposed to domestic economic health and local pharmacy benefit manager trends.
Cardinal Health, Inc. (CAH) is highlighted as a potential value investment opportunity, currently holding a Zacks Rank of #2 (Buy) and an "A" grade in the Value category according to Zacks Investment Research's Style Scores system. The article notes that Cardinal Health trades with a Price-to-Earnings-and-Growth (PEG) ratio of 1.24, which is below its industry average of 1.76 and compares favorably to the stock's own recent range between 1.22 and 1.88. Additionally, the company exhibits a Price-to-Cash-Flow (P/CF) ratio of 15.27, slightly underpinning the sector average of 15.38, while maintaining a historical median P/CF around 15.12 over the past 52 weeks.
The analysis suggests these metrics indicate the stock is undervalued relative to its growth outlook and industry peers. To provide further context for value-focused investors, the content draws a parallel to The Cooper Companies (COO), which shares similar attributes with a Zacks Rank #2 and an "A" Value score, though with slightly different valuation figures such as a Forward P/E of 15.59 compared to a lower industry average of 15.32. Both companies are presented as solid examples in the Medical-Dental Supplies sector for investors seeking undervalued positions based on fundamental metrics and earnings strength.
📈 Cardinal Health holds a Zacks Rank #2 with an A-grade Value score.
💰 Its PEG ratio of 1.24 is significantly lower than the industry average.
💸 The stock's P/CF ratio remains competitively valued relative to peers.
🏥 Cooper Companies also shows strong value metrics including a low P/B ratio.
⚠️ Both firms offer attractive earnings outlooks for strategic value investors.
📈 Cardinal Health (CAH) holds a Zacks Rank #2 (Buy) and an A-grade in the Value category according to the Style Scores system.
💰 CAH has a PEG ratio of 1.24, which is significantly lower than its industry average of 1.76, suggesting potential undervaluation relative to earnings growth.
💸 The stock's Price-to-Cash-Flow (P/CF) ratio stands at 15.27, compared to an industry average of 15.38, indicating it is competitively valued based on cash flow metrics.
🏥 For comparison, The Cooper Companies (COO) also carries a Zacks Rank #2 and an A-grade Value score in the medical supplies sector.
📊 COO's Forward P/E ratio of 15.59 is slightly below its industry average of 15.32, while its PEG ratio of 1.67 mirrors the market norm of 1.76.
📉 The Cooper Companies' P/B ratio of 1.62 is notably lower than the industry average of 4.56, highlighting a potentially undervalued asset base.
📈 Analysts suggest both CAH and COO represent strong value stocks currently given their impressive earnings outlooks and favorable valuation metrics.
💡 Value investors typically look for specific traits like high Zacks Rank grades combined with A-level Value scores to identify great companies.
🛑 While PEG ratios have fluctuated over the last 12 months, CAH's median of 1.49 remains below the industry average, supporting a buy rating.
⚠️ Investors are advised to consider both earnings estimates and individual strategies when deciding whether to purchase these value-oriented stocks.
Bullish Signals
Cardinal Health (CAH) holds Zacks Rank #2 Buy.
Stock earns 'A' grade in the Value category.
PEG ratio of 1.24 is below industry average.
P/CF ratio of 15.27 signals strong cash flow.
Risk Factors
No mentioned downside risks for Cardinal Health (CAH).
Text lacks competitive threat analysis.
Implies zero negative sentiment in financial outlook.
Bullish Signals
Cardinal Health (CAH) holds a Zacks Rank #2 (Buy), indicating strong potential based on earnings estimates and revisions.
The stock also carries an 'A' grade in the Value category, positioning it as one of the strongest value stocks on the market today.
CAH has a PEG ratio of 1.24, which is significantly lower than its industry average of 1.76, suggesting attractive earnings growth relative to price.
The company's P/CF ratio stands at 15.27, which is more attractive than the industry average of 15.38 and signals strong cash flow.
Over the past 52 weeks, CAH's PEG ratio ranged from a low of 1.22 to a median of 1.49, demonstrating consistent value metrics compared to its sector.
Risk Factors
The article presents Cardinal Health (CAH) as a strong value stock with a 'Buy' Zacks Rank and an 'A' grade, lacking any mention of potential downside risks or competitive threats.
Analysts are suggesting that CAH is currently undervalued, which implies there is little to no negative sentiment regarding its current financial outlook within the text.
Cardinal Health, Inc. (NYSE:CAH) is featured in an article titled "5 Best Fortune 500 Stocks to Buy According to Analysts," which highlights recent positive sentiment and financial performance from the medical distribution giant. On May 1, TD Cowen analyst firm increased its price target for Cardinal Health's stock from $251 to $255 while maintaining a "Buy" rating. The adjustment reflects an estimated upside of 30% from current trading levels and follows an updated analyst model based on the company's quarterly report.
The article details Cardinal Health's Q3 results, released on April 30, noting that adjusted earnings per share reached $3.17, which significantly beat estimates by $0.38. However, total revenue of nearly $61 billion fell short of expectations by $1.3 billion, even though the company reported year-over-year growth of 11%. The decline in revenue was specifically attributed to impacts from the Inflation Reduction Act on wholesale acquisition costs for drugs.
Looking ahead, Cardinal Health raised its full-year 2026 adjusted earnings per share target range to between $10.70 and $10.80 per share, up from a previous forecast of $10.15 to $10.35 and beating the analyst consensus of $10.31 per share. The company's operations encompass pharmaceutical distribution, specialty products, home-health services, nuclear pharmacies, manufacturing facilities, and medical laboratory products globally.
📈 TD Cowen upgrades CAH price target to $255 with 30% upside.
💰 Q3 adjusted EPS of $3.17 beat estimates by $0.38.
📉 Revenue fell short of expectations due to sector slowdowns.
💊 Pharma revenue slowed from Inflation Reduction Act impacts.
🏥 Cardinal Health (CAH) is a Fortune 500 company operating as a global distributor of pharmaceuticals, medical products, and laboratory solutions.
📈 TD Cowen upgraded its price target on CAH from $251 to $255 while maintaining a "Buy" rating, indicating a 30% upside.
💰 The analyst's move follows the company's Q3 report where adjusted earnings of $3.17 per share significantly beat estimates by $0.38.
📉 Despite strong earnings, CAH's revenue of nearly $61 billion fell short of expectations due to growth in other sectors.
💊 Pharmaceutical revenue specifically slowed due to Inflation Reduction Act changes impacting wholesale acquisition costs.
🎯 Cardinal Health raised its full-year 2026 adjusted EPS target to between $10.70 and $10.80, surpassing analyst consensus.
⚙️ Analysts updated their models based on the quarterly results to reflect the new operational realities for the healthcare giant.
Bullish Signals
TD Cowen raised Cardinal Health target to $255 on May 1.
New target implies 30% upside from current price levels.
Earnings beat estimates by $0.38 at $3.17 per share.
Management raised full-year 2026 EPS target to $10.70-$10.80.
Guidance raised above analyst consensus and previous forecast.
Risk Factors
Revenue missed expectations by $1.3 billion.
Pharma growth hit by Inflation Reduction Act.
Strong earnings mask core business weakness.
Bullish Signals
On May 1, TD Cowen raised its price target on Cardinal Health from $251 to $255 while maintaining a 'Buy' rating.
The new target implies an upside of 30% from current price levels for the stock.
Cardinal Health reported Q3 adjusted earnings of $3.17 per share, beating analyst estimates by $0.38.
Despite missing revenue expectations, Cardinal Health achieved year-over-year revenue growth of 11%.
Management demonstrated confidence by raising its full-year 2026 adjusted EPS target to $10.70-$10.80 per share.
The company raised its guidance above both its previous forecast and the analyst consensus estimate.
Risk Factors
Cardinal Health's revenue of almost $61 billion fell short of expectations by $1.3 billion, indicating a significant miss in top-line performance despite year-over-year growth.
The company's Pharmaceutical revenue growth was explicitly hurt by changes related to the Inflation Reduction Act impacting wholesale acquisition costs of drugs.
Despite reporting strong Q3 earnings, the substantial revenue miss suggests potential underlying weakness in its core business operations or market demand.
Cardinal Health (CAH) has experienced a recent downtrend, losing 8.8% over the past two weeks, but technical analysis suggests a potential reversal following the formation of a hammer chart pattern on its last trading session. This candlestick pattern indicates that while the stock opened lower and dipped to a new low, it found support near the bottom with buying interest pushing the price up to close near or above the opening level, signaling that bears may have lost control. The length of the lower wick was at least twice the body of the candle, confirming the hammer shape which typically suggests exhaustion of selling pressure and a possible trend change for both short-term and long-term investors.
Beyond technical signals, fundamental factors are supporting a bullish outlook for Cardinal Health as Wall Street analysts have shown rising optimism regarding future earnings. Consensus EPS estimates for the current year have increased by 4.4% over the last 30 days, reflecting a positive trend in earnings estimate revisions that often translates into near-term price appreciation. The company currently holds a Zacks Rank of #2, placing it in the top 20% among more than 4,000 stocks based on trends in earnings estimates and EPS surprises, which historically leads to outperformance relative to the broader market.
The combination of the technical hammer pattern and upward momentum in analyst revisions strengthens the case for a bottom forming soon in Cardinal Health's stock. A Zacks Rank #2 is particularly viewed as a conclusive timing indicator that helps investors identify when a company's prospects are beginning to improve, suggesting that CAH could be poised for continued gains as the market digests these positive developments and potential earnings beat expectations materialize.
📉 CAH dropped 8.8% but formed a bullish hammer pattern signaling exhaustion.
💡 Rising EPS estimates and a Zacks Rank #2 support near-term price appreciation.
🔄 Fundamental optimism and technical signals combine to suggest a potential trend reversal.
📉 Cardinal Health (CAH) recently lost 8.8% over two weeks but may be nearing a bottom after forming a hammer chart pattern.
🕯️ The hammer pattern indicates selling pressure exhaustion, characterized by a small body and a long lower wick that is at least twice the length of the body.
💡 This technical formation suggests bulls are counteracting bears, signaling potential loss of bearish control over the stock price.
📈 Fundamental optimism is driving analyst expectations, evidenced by a 4.4% increase in consensus EPS estimates for the current year over the last 30 days.
🔄 An upward trend in earnings estimate revisions typically translates into near-term price appreciation for CAH.
🥈 The stock currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by earnings trends and surprises.
🚀 Stocks with a Zacks Rank #1 or #2 have historically shown the ability to outperform the broader market.
⏱️ The Zacks Rank serves as an effective timing indicator that helps pinpoint when a company's future prospects are improving.
🛠️ Investors are advised to use the hammer pattern alongside other bullish indicators, as it has limitations and depends on chart placement.
📊 Cardinal Health operates as a major prescription drug distributor facing a potential trend reversal based on combined technical and fundamental factors.
Bullish Signals
Hammer pattern after an 8.8% decline signals reversal.
Rising analyst optimism provides solid fundamental support.
Consensus EPS estimate increased 4.4% in 30 days.
Cardinal Health holds a Zacks Rank #2 Buy.
Rank #1/2 stocks historically outperform the market.
Risk Factors
Stock lost 8.8% in two weeks showing bearish sentiment.
Cardinal Health shows a persistent downtrend indicating weakness.
Hammer patterns need confirmation as a standalone indicator.
Zacks Rank #2 Buy falls short of top-tier #1.
Bullish Signals
A hammer chart pattern was formed in Cardinal Health's last trading session, signaling a potential trend reversal after a recent 8.8% decline.
Rising optimism among Wall Street analysts regarding future earnings is providing a solid fundamental factor to support the stock.
The consensus EPS estimate for the current year has increased by 4.4% over the last 30 days, indicating improving analyst expectations.
Cardinal Health currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks based on earnings trends and surprises.
Historically, stocks with a Zacks Rank #1 or #2 have outperformed the market, suggesting a strong potential for upside.
Risk Factors
The stock has lost 8.8% over the past two weeks, indicating recent significant selling pressure and bearish sentiment.
A downtrend has been apparent in Cardinal Health lately, suggesting ongoing weakness despite any potential technical reversal signals.
Hammer chart patterns have limitations as a standalone indicator; they require confirmation from other bullish indicators to be reliable.
While currently holding a Zacks Rank #2 (Buy), the stock is not ranked #1 (Strong Buy), which suggests it may not be in the very top tier of performing stocks.
Jim Cramer's Charitable Trust is increasing its holdings in Cardinal Health (CAH) by purchasing 50 shares at approximately $199 per share. This transaction brings the trust's total ownership to 525 shares, raising the position's weight in the portfolio from 2.50% to 2.75%. The team is acquiring these shares following a decline in stock price after the company reported earnings for fiscal third quarter 2026.
Management and analysts remain confident in Cardinal Health's long-term ability to grow earnings per share in the low-to-mid teens, despite missing revenue expectations and reporting $184 million in impairment charges for its Navista and ION reporting units. Consequently, many analysts have raised their fiscal year 2027 earnings per share estimates; the consensus on FactSet has increased from about $11.60 to $11.91 following the report.
The negative price action combined with higher long-term earnings projections has made the stock appear significantly more attractive compared to one week ago. Current shares are trading at roughly 16.5 times the next twelve months' estimates, down from approximately 20 times earnings when the trust initially took its stake in early March. The CNBC Investing Club notes that Jim Cramer waits specific periods after issuing trade alerts before executing trades for his charitable trust, subject to standard terms and conditions with no fiduciary obligation or profit guarantee.
🚀 Jim Cramer's Trust bought more Cardinal Health shares after a dip.
💰 Valuation is attractive at 16.5x estimates versus a March high of 20x.
🚀 Jim Cramer's Charitable Trust increased its holding in Cardinal Health (CAH) by purchasing 50 additional shares at approximately $199.
📉 The trade capitalizes on a post-earnings decline, though the report initially showed a revenue miss and $184 million in impairment charges for specific reporting units.
📈 Analyst confidence remains high, with many raising their fiscal year 2027 earnings per share estimates to $11.91 from about $11.60 prior to the release.
💰 The stock's valuation has become attractive, trading at roughly 16.5 times next twelve months' estimates compared to a high of around 20 times in early March.
🤝 Management and the analyst community maintain confidence in Cardinal Health's ability to grow earnings per share in the low-to-mid teens over the long term.
📊 Following this purchase, the trust's total holding increased to 525 shares, representing a portfolio weight of 2.75% up from 2.50%.
⏳ Trading for CNIBC subscribers follows specific rules, such as waiting 45 minutes after sending an alert or 72 hours if the stock was discussed on CNBC TV.
📝 The article includes standard disclaimers stating that information is subject to terms and conditions, with no fiduciary obligation or guaranteed outcomes.
Bullish Signals
Charitable Trust adds shares in Cardinal Health (CAH) at $199.
Analysts raise FY2027 EPS estimate to $11.91 on FactSet.
Stock trades at ~16.5x earnings, down from ~20x in March.
The Charitable Trust is adding shares to its position in Cardinal Health (CAH) following a post-earnings price decline, increasing its holding to 525 shares at an attractive entry point of roughly $199.
Both management and the analyst community express confidence in Cardinal Health's ability to grow earnings per share in the low-to-mid teens over the long term, prompting many analysts to raise their fiscal year 2027 EPS estimate from $11.60 to $11.91 on FactSet.
The stock is trading at a mid-teens price-to-earnings multiple of roughly 16.5 times next 12 months estimates, which represents a significant discount compared to the approximately 20x earnings multiple seen in early March.
Analysts have raised their consensus earnings estimate for fiscal year 2027 despite a recent revenue miss and impairment charges, indicating strong upside potential in future growth projections.
Risk Factors
Cardinal Health missed revenue expectations in its fiscal 2026 third quarter report.
The company recorded $184 million in impairment charges specifically for its Navista and ION reporting units, impacting overall profitability.
Shares recently experienced a price decline following the earnings announcement, indicating short-term negative market sentiment.
Kevin Stankiewicz from the Investing Club argues that Cardinal Health's (CAH) significant sell-off on Thursday was an overreaction and expresses a strong desire to buy shares if not restricted by CNBC trading rules. The author notes that Jim Cramer mentioned the stock on CNBC TV on Thursday, which triggers a mandatory 72-hour wait for his charitable trust before executing trades, preventing an immediate purchase despite their bullish thesis. Cardinal Health's quarterly results showed a top-line miss and a surprise $184 million goodwill impairment charge related to its Navista and ION reporting units within the management services organizations (MSOs) business line, which Cramer wished had been better telegraphed by management. However, CEO Jason Hollar reassured investors that this accounting event will not alter the company's strategic direction for MSOs.
The core investment thesis relies on Cardinal Health's history of delivering double-digit earnings-per-share growth and its positioning within secular tailwinds such as an aging U.S. population. The company has successfully expanded into higher-margin areas including specialty pharmaceutical distribution, at-home delivery, and non-distribution businesses like MSOs. Financial metrics support the buy view, as the stock is trading at approximately 16.5 times next 12 months' estimates per FactSet data, down from around 20 times earnings when the club established its stake in early March. This valuation compression provides a margin of safety while management remains confident in guiding adjusted earnings growth for fiscal 2027 within its long-term target range of 12% to 14%.
Wall Street analysts largely agree with this sentiment, reinforcing that the pullback presents an opportunity rather than a risk. Jefferies stated its thesis on Cardinal remains unchanged, while Leerink Partners noted that momentum remains robust and investors' high expectations were not fully supported by the "print." The club views healthcare stocks generally as being out of favor in the current market, creating a situation where a quality company like Cardinal could be a leading candidate when sentiment improves. They describe Cardinal as "a good house in a bad neighborhood," suggesting it should be purchased first once the broader sector begins to recover from its recent underperformance and rotation moves.
📉 Stock dropped 4.9% after missing top-line expectations and recording an $184M impairment charge.
⏱️ CEO confirms strategy remains unchanged despite recent financial setbacks and trading restrictions.
👵 Long-term growth relies on an aging population and expansion into specialty pharma distribution.
📈 Shares currently trade at ~16.5x earnings, down from 20x earlier in the year.
✨ Analysts view the decline as an overreaction to a company with a strong track record.
📉 Cardinal Health's stock dropped 4.9% following its quarterly earnings report on Thursday.
✋ Analysts from the firm consider this decline an overreaction and state they would buy shares if allowed to trade.
⏱️ Jim Cramer mentioned Cardinal on CNBC TV, triggering a 72-hour trading restriction for his charitable trust which prevents an immediate purchase.
📈 The investment thesis is built on the company's track record of delivering double-digit earnings-per-share growth.
👵 A key positive driver is Cardinal's exposure to the secular trend of an aging U.S. population.
💊 The company has expanded into faster-growing, higher-margin areas such as specialty pharmaceutical distribution and management services organizations.
⚠️ Thursday's fiscal 2026 third-quarter report missed top-line expectations and included a $184 million goodwill impairment charge for its Navista and ION reporting units.
🗣️ CEO Jason Hollar confirmed that this impairment will not change their strategy regarding the MSO business line.
🎯 Management remains confident in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.
📊 Based on those estimates, Cardinal's shares are now trading at approximately 16.5 times next 12-month earnings, down from about 20x in early March.
🤝 Multiple Wall Street analysts, including Jefferies and Leerink Partners, have defended the stock and see no reason for the share price to be off without a massive rotation.
💧 Cardinal is described as a "good house in a bad neighborhood" within the healthcare sector, which currently has stocks that are out of favor.
🔄 When healthcare sentiment improves, analysts believe this well-positioned company will be among the first to be bought by investors.
Bullish Signals
Cardinal Health has a track record of delivering double-digit earnings-per-share growth, supported by the secular tailwind of an aging U.S. population.
The company has successfully expanded into faster-growing, higher-margin areas including specialty pharmaceutical distribution, at-home delivery, and management services organizations (MSOs).
CEO Jason Hollar reaffirmed confidence in growing adjusted earnings for fiscal 2027 within the long-term target range of 12% to 14%.
Valuation appears attractive as shares are trading at roughly 16.5 times the next 12 months' estimates, down from about 20x earnings when the stake was taken in early March.
Major Wall Street analysts support the positive outlook; Jefferies stated its thesis on Cardinal Health remains unchanged despite recent market overreaction.
Leerink Partners notes that momentum for Cardinal Health remains robust and that a pullback presents an opportunistic buying opportunity.
Risk Factors
Cardinal Health's stock price declined by 4.9% on Thursday following an earnings miss.
The company booked a $184 million goodwill impairment charge for its Navista and ION reporting units, creating market noise despite management's strategy remaining unchanged.
The article explicitly states that the top-line earnings report missed investor expectations.
Cardinal Health traded at roughly 16.5 times forward earnings in late September, a significant drop from the approximately 20 times multiple seen in early March when the author took a stake.
Cardinal Health, Inc. reported third-quarter fiscal 2026 results that exceeded analyst expectations for earnings per share but fell short on revenue. The company's adjusted EPS reached $3.17, surpassing the Zacks Consensus Estimate of $2.80 by 13.2%, while GAAP EPS stood at $1.69 compared to $2.10 in the prior-year period. Sales totaled $60.94 billion, representing an 11% year-over-year increase but missing estimates by 2.3%. The strong earnings performance was driven primarily by the Pharmaceutical segment, where revenues grew 11% to $56.11 billion and profits rose 18% to $784 million, aided by brand sales growth and positive generic program performance.
The Medical Products and Distribution segment contributed mixed results, with revenues of $3.15 billion remaining flat due to lower distribution volumes offset by Cardinal Health brand growth. Despite this, the segment's profit dropped 36% to $25 million, mainly impacted by adverse net tariffs, though specific sub-segments like at-Home Solutions saw a 34% profit increase to $179 million. Overall company cash and cash equivalents increased significantly to $3.94 billion from $2.78 billion in the previous quarter, and operating cash flow surged to $3.48 billion from $877 million year-over-year. Gross margins improved to 4.1%, up 20 basis points, despite a 36% rise in SG&A expenses.
Looking ahead, Cardinal Health raised its fiscal 2026 guidance, anticipating adjusted EPS between $10.70 and $10.80, which represents a significant increase from the previous outlook of $10.15 to $10.35. The company projects Pharmaceutical segment revenues to grow 15-17% with segmental profit increasing 22-23%. Strategic initiatives highlighted include the acquisition of Solaris Health, which added over 750 providers to the urology specialty alliance, and continued investment in nuclear medicine capabilities via the expansion of Actinium-225 production. The company also maintained a disciplined capital allocation strategy, having reduced debt and repurchased shares totaling $1.0 billion year-to-date alongside regular dividend payments. Consequently, Cardinal Health's stock gained 0.4% in pre-market trading after reporting these mixed but ultimately positive results for long-term value creation.
📈 Q3 adjusted EPS hit $3.17, beating estimates by 13.2% and rising 35% year-over-year.
💊 Pharma revenues and profits surged 11% and 18%, driving overall earnings growth.
⚠️ Tariff impacts hurt Medical Products profit, though operating income remains robust.
🔢 Guidance raised for fiscal 2026 EPS range to $10.70-$10.80.
💰 Cash reserves climbed to $3.94 billion while debt was reduced ahead of schedule.
📈 Cardinal Health reported third-quarter fiscal 2026 adjusted EPS of $3.17, beating the consensus estimate of $2.80 by 13.2%.
💰 Adjusted earnings per share represented a 35% year-over-year improvement in the bottom line.
💵 GAAP EPS for the quarter was $1.69 compared to $2.10 in the prior year period.
📉 Sales reached $60.94 billion, reflecting an 11% year-over-year increase but missing consensus estimates by 2.3%.
💊 Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth.
🏭 Pharmaceutical profits totaled $784 million, a 18% increase from the previous year due to positive generics program performance.
📦 Global Medical Products and Distribution revenue remained flat at $3.15 billion, partially offsetting lower distribution volumes.
⚠️ The Global Medical Products segment profit dropped 36% to $25 million primarily due to adverse tariff impacts.
💉 At-Home Solutions and Nuclear segments within Global Medical grew significantly with sales up 31% and profit up 34%.
🔄 Gross margin increased to 4.1% of revenues, an improvement of almost 20 basis points year over year.
💸 Operating income decreased 30.3% to $509 million, while adjusted operating income rose 18.5% to $956 million.
🏦 The company ended the quarter with cash and equivalents of $3.94 billion, up from $2.78 billion in the prior quarter.
🚀 Cardinal Health raised its fiscal 2026 adjusted EPS guidance range to $10.70-$10.80 from $10.15-$10.35.
🛠️ The Pharmaceutical segment profit is now expected to grow 22-23% compared to the previous guidance of 20-22%.
💻 Shares of Cardinal Health rose 0.4% in pre-market trading despite a revenue miss but earnings beat.
🏥 Cardinal Health acquired Solaris Health to expand its urology presence, adding over 750 providers across 14 states.
⚡ The company expanded Actinium-225 production capabilities at its Nuclear and Precision Health Solutions Center for Theranostics Advancement.
💰 Management maintained a disciplined capital allocation strategy with debt reduced ahead of schedule and $1 billion in share repurchases.
Bullish Signals
EPS beat estimates by 13.2% with full-year improvement of 35%.
Pharmaceutical revenues grew 11% to $56.11 billion.
Pharmaceutical profit increased 18% to $784 million.
Nuclear segment sales surged 31% and profit up 34%.
Raised fiscal 2026 EPS guidance to $10.70-$10.80.
Cash grew significantly to $3.94 billion.
Reduced debt and returned $1.0B to shareholders.
Acquired Solaris Health adding 750 providers in 14 states.
Expanding Actinium-225 production for targeted therapies.
Risk Factors
GAAP EPS fell to $1.69 from $2.10 despite adjusted beat.
Revenues of $60.94B missed estimates by 2.3%.
Operating income dropped 30.3% year over year.
Medical segment profit down 36% due to tariff impacts.
Distribution expenses rose 17.3%, squeezing margins.
Analysts expect only 1-3% Medical growth vs other sectors.
Stock lost 1.3% YTD while S&P 500 gained 4.5%.
Debt cuts may limit future acquisitions or capital expenditure.
Bullish Signals
Cardinal Health reported Q3 adjusted EPS of $3.17, beating analyst estimates by 13.2% with a full-year improvement of 35% year over year.
Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth from existing customers.
Pharmaceutical profit increased 18% to $784 million due to positive generics program performance and contributions from brand products.
Sales in the Nuclear and Precision Health Solutions segment surged 31% year over year, contributing to a 34% profit increase to $179 million.
The company raised its fiscal 2026 adjusted EPS guidance to $10.70-$10.80, representing 30-31% growth compared to the previous outlook.
Cardinal Health increased its Pharmaceutical segment profit guidance to 22-23% growth and Other segment profit guidance to 36-38% growth.
Cash and cash equivalents grew significantly to $3.94 billion from $2.78 billion, while net cash provided by operating activities jumped to $3.48 billion.
The company strengthened its balance sheet by reducing debt ahead of schedule and returning $1.0 billion to shareholders via share repurchases and dividends year to date.
The acquisition of Solaris Health added over 750 providers in 14 states, expanding The Specialty Alliance's reach to approximately 3,000 providers across 33 states.
Shares were up 0.4% in pre-market trading and underperformed the broader market declines, losing only 1.3% year-to-date versus the industry's 6.1% decline.
The company is expanding Actinium-225 production capabilities to support next-generation targeted therapies and data-driven healthcare solutions.
Risk Factors
While adjusted EPS beat estimates, GAAP EPS actually declined to $1.69 from $2.10 in the year-ago period, indicating underlying profitability headwinds.
Total revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%, revealing growth execution challenges despite top-line expansion efforts.
Operating income dropped 30.3% year over year to $509 million, a significant deterioration in core profitability that contrasts with adjusted earnings.
The Global Medical Products and Distribution segment reported a profit of only $25 million, down 36% from the prior year, primarily due to adverse net impacts from tariffs.
Distribution expenses increased 17.3% year over year to $1.54 billion, rising at a faster rate than revenues and squeezing margins.
Revenue growth estimates for the Medical segment are conservative, with analysts expecting only 1-3% growth compared to higher growth in other sectors.
The company faces competitive pressure as its stock has lost 1.3% year-to-date while the S&P 500 Index has gained 4.5%, underperforming the broader market.
Debt reduction and share repurchases, while positive, may limit future strategic acquisitions or capital expenditure if growth slows.
Cardinal Health (CAH) reported Q3 earnings per share of $3.17, surpassing the Zacks Consensus Estimate of $2.80 and significantly exceeding the year-ago figure of $2.35. The quarterly results reflect a positive earnings surprise of 13.22%, continuing a streak where the company has beaten consensus EPS estimates for four consecutive quarters. However, total revenues for the quarter ended March 2026 were recorded at $60.94 billion, which missed the consensus estimate by 2.27%. Despite this revenue miss, the stock remains in a positive technical setup according to Zacks analysis, maintaining a Zacks Rank of #2 (Buy) due to favorable earnings estimate revisions ahead of the release.
Analysts note that while Cardinal has underperformed the broader market with shares down approximately 1.3% versus the S&P 500's gain of 4.2% since the start of the year, the company's immediate price trajectory is likely to depend on management's commentary during the earnings call. The current consensus outlook projects $10.32 per share for the fiscal year and $2.34 for the upcoming quarter against projected revenues of $259.11 billion and $67.23 billion respectively. Furthermore, the company operates in the Medical - Dental Supplies industry, which currently ranks in the top 22% among all Zacks industries, suggesting a positive sector-wide performance potential that typically drives better returns than the bottom half of sectors.
The article concludes by highlighting the importance of tracking earnings estimate revisions as a reliable metric for predicting short-term stock movements. While Cardinal Health reported its figures, the text also briefly mentions peers like Lifevantage (LFVN), which has yet to report results but is expected to show a significant decline in earnings and revenue in the upcoming quarter. Overall, the report frames Cardinal Health as a stock with strong recent earnings momentum supported by a solid industry rank and positive consensus trends, despite the minor revenue shortfall in the latest quarter.
💰 Cardinal Health beat EPS estimates by 13.22% to reach $3.17 per share.
📉 Revenue missed consensus projections by 2.27% despite year-over-year growth.
⚠ Stock underperformed the S&P 500, gaining only 4.2% vs Cardinal's loss.
💰 Cardinal Health reported Q3 earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.80 and beating last year's $2.35 per share.
📈 The quarterly earnings surprise was +13.22%, following a previous quarter that also beat estimates by +10.04%.
✅ Over the trailing four quarters, Cardinal Health has exceeded consensus EPS estimates in four out of four instances.
📉 Revenue for the quarter ended March 2026 came in at $60.94 billion, which missed the Zacks Consensus Estimate by 2.27% despite rising from last year's $54.88 billion.
🔄 Cardinal has exceeded revenue estimates twice over the last four quarters.
⚠️ Analysts note that the sustainability of stock price movement will depend on management commentary during the earnings call.
📉 Cardinal Health shares have underperformed, losing about 1.3% year-to-date compared to the S&P 500's 4.2% gain.
📊 The Zacks Rank for Cardinal is #2 (Buy), driven by favorable estimate revisions and a strong correlation between these trends and near-term stock movements.
🔮 Current consensus estimates project $2.34 EPS and $67.23 billion revenue for the coming quarter, alongside $10.32 EPS and $259.11 billion revenue for the fiscal year.
🏥 Cardinal Health belongs to the Zacks Medical - Dental Supplies industry, which is currently ranked in the top 22% of all industries.
🆚 Peer company Lifevantage (LFVN) has not yet reported its Q3 results, which are expected on May 6 with estimated earnings of $0.16 per share.
⬇️ For Lifevantage, analysts expect revenues of $47.82 million, representing an 18.2% year-over-year decline.
Bullish Signals
Cardinal Health beat estimates with $3.17 EPS (+13.22%),.
Consistently exceeded consensus in 4/4 last quarters.
Holds Zacks Rank #2 Buy rating.
In top 22% high-performing industry sector.
Y/Y earnings grew from $2.35 to $3.17.
Risk Factors
Cardinal Health revenue missed analyst estimates despite beating earnings.
Stock lost 1.3% this year, underperforming the S&P 500's 4.2% gain.
Future performance hinges on management commentary rather than current results.
Peer Lifevantage faces a significant -38.5% drop in expected earnings.
Bullish Signals
Cardinal Health reported quarterly earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.8 per share with a positive surprise of +13.22%.
The company has exceeded consensus EPS estimates in four out of the last four quarters, demonstrating consistent performance strength.
Cardinal currently holds a Zacks Rank #2 (Buy), indicating strong potential to outperform the market in the near future based on favorable earnings estimate revisions.
The Medical - Dental Supplies industry ranks in the top 22% of all Zacks industries, positioning Cardinal within a high-performing sector that historically outperforms the bottom half by more than 2 to 1.
Year-over-year earnings increased from $2.35 per share to the current $3.17 per share, reflecting robust business growth after adjusting for non-recurring items.
Risk Factors
Cardinal Health's quarterly revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.27%, indicating a downward revision in analyst expectations despite an earnings beat.
The company's stock price has lost approximately 1.3% since the beginning of the year, significantly underperforming the S&P 500's gain of 4.2% during the same period.
Investors face uncertainty regarding future stock performance as the sustainability of recent price movements depends heavily on management's upcoming commentary rather than immediate financial results.
A peer competitor in the same industry, Lifevantage (LFVN), reports a significant decline in expected earnings with an EPS of $0.16 representing a -38.5% year-over-year change.
Shares of Cardinal Health (CAH) fell more than 6% on Thursday following the release of mixed quarterly results for the period ending March 31. While revenue grew 11% year over year to $60.94 billion, it missed analyst expectations of $61.7 billion across all three operating segments. Despite the revenue miss, adjusted earnings per share (EPS) beat consensus estimates at $3.17 compared to the expected $2.79, and free cash flow reached three times the Street's estimate. Jim Cramer characterized the performance as "good, not great," noting that while overall profitability remained strong, the Global Medical Products and Distribution segment was significantly weighed down by tariff exposure and lower distribution volumes.
The company management raised its full-year earnings outlook by 50 cents at the midpoint, but noted that only 13 cents of this increase is driven by improved operational performance, with the remainder coming from tax benefits, share repurchases, and interest/other expenses. Revenue in the Pharmaceutical and Specialty Solutions segment rose 11% to $56.2 billion, fueled largely by a 30% surge in revenue for obesity and weight-loss medicines (GLP-1s), which contributed a 6-percentage-point increase to segment revenue. Conversely, Global Medical Products and Distribution revenue was flat at $3.25 billion, though segment profit plummeted 35% year over year due to tariffs. The Other segment saw a robust 31% revenue increase to $1.7 billion, driven by growth in Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
Analysts are reacting to the mixed report by adjusting their positions on the stock. At a trading price of approximately $190, shares are valued at about 16 times fiscal year 2027 estimates, marking the lowest multiple seen since October and entering oversold territory based on the Relative Strength Index (RSI). Although the valuation sits on the lower end of the historical range of 15-21 times, the stock remains near its 200-day moving average. Consequently, the analysts have trimmed their price target from $260 to $225 and are maintaining a "Buy" rating, advising patience while the market digests the sell-off. CEO Jason Hollar reiterated the company's strategic focus on simplification, cost optimization, and supply chain resiliency as they navigate the dynamic tariff environment.
📉 Revenue missed expectations at $60.94B despite an 11% year-over-year growth.
💰 Adjusted earnings beat estimates significantly at $3.17 per share.
⚠️ Tariffs caused profit drops in distribution while GLP-1 demand surged in pharma.
📉 Cardinal Health shares are dropping after reporting mixed quarterly results that disappointed investors on revenue but beat earnings estimates.
💰 Revenue for the quarter ended March 31 grew 11% year-over-year to $60.94 billion, missing analyst expectations of $61.7 billion according to LSEG.
🧮 Adjusted earnings per share came in at $3.17, which beat the consensus estimate of $2.79 compiled by LSEG.
⚠️ Jim Cramer described the company's performance as "Good, not great" during his Morning Meeting segment on Thursday.
📉 While overall profitability remained strong and free cash flow tripled Street estimates, sales missed targets across all three operating segments.
🏭 The Global Medical Products and Distribution segment faced significant challenges due to lower distribution volumes and the negative impact of tariffs.
💊 Revenue in the Pharmaceutical and Specialty Solutions segment rose 11% to $56.2 billion, driven by strong demand for GLP-1 weight-loss drugs which grew over 30%.
📉 The Other segment saw a 31% revenue increase to $1.7 billion, though it still fell short of Wall Street expectations.
⚖️ In Global Medical Products and Distribution, profits plummeted by 35% year-over-year primarily due to tariff-related costs offsetting revenue gains from brand products.
🔼 Management raised its full-year earnings outlook, but noted that only 13 cents of the $0.50 increase stems from operational improvements rather than taxes or expenses.
📉 The stock is currently trading around $190 with a forward P/E ratio of 16x fiscal year 2027 estimates, which is at the lower end of its valuation range over the past year.
⚠️ Analysts are maintaining their "Buy" rating but trimming the price target from $260 to $225 while waiting for more clarity on the situation.
📉 Technical indicators show the stock has entered oversold territory with a Relative Strength Index (RSI) cross, suggesting significant pessimism is baked into the price.
🛑 The stock is hovering near its 200-day moving average support level after being down more than 6%, making investors cautious about rushing in at the dip.
🏢 CEO Jason Hollar emphasized that cost optimization initiatives are delivering results while the company navigates a dynamic and challenging tariff environment.
Bullish Signals
Revenue for the three months ended March 31 increased 11% year over year to $60.94 billion, demonstrating solid top-line growth despite missing high expectations.
Adjusted earnings per share (EPS) came in at $3.17, significantly beating the consensus estimate of $2.79 by approximately 14%.
Free cash flow was three times the Street's consensus estimate, indicating strong operational efficiency and cash generation capabilities.
Management raised its full-year earnings outlook, signaling confidence in the company's long-term trajectory despite recent mixed results.
Revenue in the Pharmaceutical and Specialty Solutions segment increased 11% year over year to $56.2 billion, driven by strong demand for brand and specialty pharmaceuticals.
The company reported a more than 30% revenue growth for obesity and weight-loss medicines (GLP-1 drugs), contributing significantly to segment revenue expansion.
In the Other segment, revenue surged 31% year over year to $1.7 billion, driven by growth across Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
CEO Jason Hollar highlighted tangible results from simplification and cost optimization initiatives, along with notable strength in the Cardinal Health brand product portfolio.
Risk Factors
Revenue missed expectations by $666 million for the quarter, with total revenue at $60.94 billion versus the consensus estimate of $61.7 billion.
The Pharmaceutical and Specialty Solutions segment revenue shorted estimates by $1.36 billion, arriving at $56.2 billion against an expected $57.56 billion.
Global Medical Products and Distribution sales were held back by lower distribution volumes, resulting in revenue missing expectations despite offsetting brand growth.
Segment profit for Global Medical Products and Distribution plummeted 35% year over year to a low of $3.25 billion, largely due to negative impact from tariffs.
The stock is down more than 6% from its recent highs and trading around the critical 200-day moving average support level.
Analyst price target has been trimmed significantly from $260 to $225 following the mixed earnings report and sell-off.
Only 13 cents of the 50-cent full-year earnings midpoint increase is attributable to operational performance, with the remainder driven by non-operational factors like taxes and share repurchases.
The stock is trading at 16 times fiscal year 2027 estimates, which is near the lowest valuation level seen since October of the previous year.
Cardinal Health reported its third quarter fiscal year 2026 results with total revenues reaching $60.9 billion, representing an 11% increase compared to the same period in fiscal year 2025. While GAAP diluted earnings per share dropped 20% to $1.69 and operating earnings fell 30% to $509 million, these declines were largely attributed to a significant $184 million pre-tax goodwill impairment charge within its Navista & ION reporting unit, which resulted from changes in risk profiles leading to higher discount rates. Conversely, non-GAAP diluted EPS rose 35% to $3.17, supported by an 18% increase in operating earnings to $956 million, lower effective tax rates, and a reduced share count, though this growth was partially offset by higher interest and other expenses.
Segment performance showed mixed but generally positive trends across the company's operations, with the pharmaceutical and specialty solutions segment leading the way. This core division recorded revenue of $56.1 billion, up 11% year-over-year, driven by growth in brand and specialty pharmaceutical sales from existing customers, alongside an 18% profit increase to $784 million due to strong performance in both brand products and the generics program. The global medical products and distribution segment saw revenue remain flat compared to the prior year, as lower distribution volumes were counterbalanced by Cardinal Health's own brand growth, though profits fell 36% to $25 million primarily due to the adverse financial impact of tariffs.
The "other" segment experienced notable expansion with revenue jumping 31% to $1.7 billion and profit rising 34% to $179 million, fueled by growth in at-Home solutions—aided by the recent acquisition of Advanced Diabetes Supply—as well as nuclear and precision health solutions and OptiFreight Logistics. CEO Jason Hollar characterized the quarter as excellent and an extension of momentum for fiscal year 2026, citing durability and resilience in the business which positions Cardinal Health for long-term value creation. Consequently, following the strong operating performance led by pharmaceuticals and specialty solutions, the company decided to raise its fiscal 2026 outlook once again. Additionally, Cardinal Health was recognized alongside AmerisourceBergen and AbbVie with perfect scores on the Barron’s 500 list for its sales volume and return on investment metrics.
💰 Revenues jumped 11% to $6.09B, with Pharma driving the majority of growth.
⚠ GAAP earnings fell 30% after a $184M goodwill impairment charge in Navista & ION.
📈 Non-GAAP earnings rose 18% as tax benefits offset higher interest expenses.
🏆 AmerisourceBergen, AbbVie, and Cardinal Health received perfect scores in Barron's 500 rankings.
💰 Cardinal Health reported Q3 fiscal year 2026 revenues of $6.09 billion (11% increase YoY).
⚠️ GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment in Navista & ION units.
📊 Non-GAAP operating earnings rose 18% to $956 million as lower tax rates and share counts offset higher interest expenses.
🗣️ CEO Jason Hollar praised the quarter's resilience, stating strong performance in pharma and specialty solutions positions them for long-term value.
💊 Pharmaceutical and specialty solutions revenue grew 11% to $5.61 billion driven by brand and specialty sales from existing customers.
📈 Profits in the pharmaceutical and specialty segment increased 18% to $784 million thanks to positive generics program performance.
🏥 Global medical products and distribution revenue remained flat YoY as lower volumes were offset by Cardinal Health's own brand growth.
📉 Medical products segment profit dropped 36% to $25 million, primarily due to the adverse net impact of tariffs.
🛠️ Other segment revenue jumped 31% to $1.7 billion, fueled by growth in at-home solutions, nuclear/precision health, and logistics.
💹 The "Other" segment profit climbed 34% to $179 million driven by acquisitions like Advanced Diabetes Supply and OptiFreight Logistics.
🏆 AmerisourceBergen, AbbVie, and Cardinal Health earned perfect scores in the Barron's 500 list of largest US/Canadian publicly traded companies.
📐 The top three companies received perfect 4.0 grade point averages based on return on investment and sales growth metrics.
Bullish Signals
Third quarter FY26 revenues hit $60.9 billion, up 11%.
Non-GAAP earnings rose 18% to $956 million.
Diluted EPS surged 35% to $3.17.
Pharma segment revenue grew 11% to $56.1 billion.
Pharma profit increased 18% to $784 million.
'Other' segment revenue jumped 31% to $1.7 billion.
'Other' segment profit rose 34% to $179 million.
FY26 outlook raised on strong operating performance.
Company earned perfect scores in Barron's 500 list.
Risk Factors
GAAP operating earnings fell 30% to $509 million.
$184 million goodwill impairment hit Navista & ION units.
Global medical revenue remained flat amid lower volumes.
Medical profit dropped 36% due to tariffs' impact.
Earnings guidance depends on momentum vulnerable to high interest.
Bullish Signals
Cardinal Health reported third quarter fiscal year 2026 revenues of $60.9 billion, representing an increase of 11% from the prior year.
Non-GAAP operating earnings increased 18% to $956 million, with diluted EPS rising 35% to $3.17.
The pharmaceutical and specialty solutions segment showed strong growth, with revenue increasing 11% to $56.1 billion.
Profit within the pharmaceutical and specialty solutions segment increased 18% to $784 million, driven by positive generics program performance.
Revenue in the 'other' segment surged 31% to $1.7 billion, driven by growth in at-Home solutions, nuclear and precision health, and OptiFreight Logistics.
Profit for the 'other' segment increased 34% to $179 million, further validating strong performance across its diverse portfolio.
CEO Jason Hollar stated that an excellent third quarter extends fiscal 2026 momentum due to the durability and resilience of the business.
Management raised their fiscal 2026 outlook based on strong operating performance and confidence in long-term value creation.
The company received perfect scores in Barron's 500 list, earning a 4.0 grade point average alongside major peers like AmerisourceBergen and AbbVie.
Risk Factors
Third quarter GAAP operating earnings decreased 30% to $509 million, with GAAP diluted EPS dropping 20% to $1.69.
The company recorded a significant $184 million pre-tax goodwill impairment in its Navista & ION reporting unit due to changes in the risk profile of business plans and an increased discount rate.
Third quarter revenue for the global medical products and distribution segment remained flat, reflecting lower distribution volumes.
Global medical products and distribution segment profit decreased 36% to $25 million, primarily driven by the adverse net impact of tariffs.
The overall earnings guidance raise relies on momentum that could be offset by high interest and other expenses noted in the non-GAAP calculations.
Cardinal Health Inc. (CAH) reported fiscal third-quarter earnings of $399 million, translating to a profit of $1.69 per share for the company headquartered in Dublin, Ohio. When adjusting for specific factors such as asset impairment costs and merger-related expenses, the adjusted earnings increased to $3.17 per share. These financial results exceeded the expectations set by Wall Street analysts, with Zacks Investment Research surveying eight experts who had projected an average earnings figure of $2.80 per share. However, despite the strong earnings beat, the company's revenue performance did not meet forecasts; Cardinal posted total revenue of $60.94 billion for the period, falling short of the $62.35 billion expected by six analysts surveyed by Zacks.
Looking ahead to the full year, Cardinal Health anticipates earnings per share in a range between $10.70 and $10.80. The report also provides context on the company's stock performance relative to broader market indices, noting that Cardinal shares have declined slightly more than 1% since the beginning of the year while the S&P 500 index has risen by 4%. Over the past 12 months, however, the stock has gained approximately 45%. This financial snapshot was generated using data from Zacks Investment Research and highlights the mixed results where profitability surpassed expectations but top-line revenue growth lagged behind analyst projections.
💰 Q3 net income hit $399M, exceeding Wall Street expectations.
📈 Adjusted earnings per share reached $3.17 versus the $2.80 consensus.
📉 Revenue fell short at $60.94B against a $62.35B forecast.
💰 Cardinal Health reported fiscal Q3 net income of $399 million, beating Wall Street expectations.
📈 Adjusted earnings came in at $3.17 per share compared to an analyst consensus of $2.80.
⚠️ Revenue for the quarter reached $60.94 billion, falling short of the estimated $62.35 billion forecast.
💼 Profit on a per-share basis was reported at $1.69 following the standard accounting adjustments.
📅 The company projects full-year earnings will range between $10.70 and $10.80 per share.
📉 Cardinal shares have declined over 1% since the start of the year despite a gain of 45% in the last 12 months.
📊 The broader S&P 500 index has risen by 4%, highlighting a performance divergence for the stock.
📋 These financial results were provided by Cardinal Health Inc., a Dublin, Ohio-based prescription drug distributor.
Despite a slight miss in revenue, Cardinal shares have gained 45% over the last 12 months, demonstrating resilience and long-term value creation for shareholders.
Risk Factors
Revenue of $60.94 billion missed Street forecasts, with analysts surveyed by Zacks expecting $62.35 billion.
Cardinal shares have dropped slightly more than 1% since the beginning of the year, trailing the S&P's 500 index which has climbed 4% during the same period.
Cardinal Health (CAH) recently traded around US$205 per share, marking a 48.7% gain over the last year and a massive 162.3% return over the past three years after a total five-year run of 272%. Simply Wall St analyzes whether this strong price appreciation has fully priced in the company's future potential or if there is still value to be captured, noting recent share price steadiness with minimal movement over the last few weeks.
The analysis utilizes a Discounted Cash Flow (DCF) model starting from a free cash flow of approximately $5.52 billion for the trailing twelve months. By projecting future cash flows through 2035 and discounting them back to present value, the DCF model estimates an intrinsic share value of roughly $540.74, implying the stock is currently undervalued by 62% based on these specific assumptions and a two-stage free cash flow to equity approach.
Valuation metrics including the Price-to-Earnings ratio are also examined, showing CAH trading at a P/E of 29.11x. This figure is compared against the Healthcare industry average of 24.34x and peer averages around 24.47x, though Simply Wall St's proprietary Fair Ratio model suggests a fair P/E of 31.16x based on earnings growth, margins, and risk factors. The current trading price is considered below this tailored Fair Ratio, further supporting the undervaluation thesis derived from the DCF model.
The article concludes by highlighting that different investors may hold varying views represented in the community, ranging from bullish analyst price targets up to US$275 to more cautious estimates around US$200. Simply Wall St notes its analysis relies on historical data and forecasts without taking into account the latest price-sensitive company announcements or qualitative material, serving as a general informational piece rather than direct financial advice to buy or sell the stock.
📉 Stock dropped 0.5% recently after massive gains of 48.7% this year and 272% over five years.
💰 DCF models suggest a $540.74 intrinsic value, implying the shares are undervalued by 62%.
📊 Current P/E ratio is slightly elevated at 29x compared to the healthcare industry average.
🎯 Simply Wall St's Fair Ratio model indicates current prices trade below the modeled fair valuation.
📉 Cardinal Health (CAH) shares recently declined 0.5% over the last month following a strong 48.7% return over the past year and a 272% gain over five years.
💰 A Discounted Cash Flow (DCF) model estimates an intrinsic value of approximately $540.74 per share, suggesting the stock is undervalued by 62% compared to the current price of ~$205.
📊 The company trades at a P/E ratio of 29.11x, which is above both the healthcare industry average (24.34x) and peer averages (24.47x).
🎯 Simply Wall St's proprietary "Fair Ratio" model determines a fair P/E of 31.16x, indicating the current shares trade below their modeled valuation level.
💧 Cardinal Health is projected to generate free cash flow of $5.52b in the last twelve months, growing to $4.75b by 2030 according to the DCF assumptions.
🤝 The stock price has stabilized recently as investors reassess risks and long-term demand within the healthcare supply chain sector.
🧠 Valuation analysis incorporates company-specific fundamentals such as earnings growth profiles and profit margins rather than relying solely on broad industry averages.
💬 Community narratives show divergent investor expectations, with bullish targets up to $275 contrasting against more cautious targets around $200.
⚠️ The article includes a standard disclaimer stating the content is based on historical data and analyst forecasts and does not constitute financial advice.
Bullish Signals
Cardinal Health rose 48.7% last year and 162.3% in three years.
D CF model values Cardinal at $540.74, implying 62% undervaluation.
Simply Wall St Fair Ratio is 31.16x vs current P/E of 29.11x.
Bullish targets project prices as high as US$275 per share.
Risk Factors
Stock declined 0.5% in last 30 days.
P/E ratio of 29.11x exceeds industry and peer averages.
Price targets range from US$200 to US$275.
Bullish Signals
Cardinal Health has delivered a strong 48.7% return over the last year and an impressive 162.3% return over the past three years.
A Discounted Cash Flow model estimates Cardinal Health's intrinsic value at $540.74 per share, implying the stock is 62.0% undervalued compared to the current price of roughly $205.
Simply Wall St's proprietary Fair Ratio for Cardinal Health is 31.16x, which is higher than the company's current P/E of 29.11x, suggesting the shares trade below their modeled fair value level.
Analyst forecasts have generated bullish price targets as high as US$275 per share, indicating potential upside for investors.
Risk Factors
The stock experienced a decline of 0.5% over the last 30 days, indicating short-term weakness despite long-term gains.
Analysts are currently predicting price targets as high as US$275, while other cautious views project targets around US$200, highlighting significant valuation uncertainty among market participants.
The P/E ratio of 29.11x is noted to be above both the Healthcare industry average of 24.34x and the peer average of 24.47x, suggesting the stock may be priced higher than its peers despite undervaluation metrics.
William Blair has initiated coverage on Cardinal Health (NYSE: CAH) with an Outperform rating, positioning the pharma distributor as a "stealth compounder" driven by a durable competitive moat. The firm highlights that Cardinal's distribution platform and scale allow it to capture value from demographic tailwinds and increasing demand for specialty medicines, particularly in the growing GLP-1 segment. This initiation coincides with a similar call on rival McKesson (MCK), signaling institutional confidence in the U.S. drug distribution oligopoly alongside Cencora (COR). Cardinal Health recently reported a 19% revenue increase to $65.63 billion in the latest quarter, with non-GAAP EPS of $2.63 beating consensus estimates.
The bull case for Cardinal centers on its pivot toward higher-margin specialty services, including recent acquisitions in urology (Solaris Health) and diabetes supply, alongside a broad platform of non-distribution services that protect profitability. CEO Jason Hollar raised fiscal 2026 EPS guidance to between $10.15 and $10.35, citing at least double-digit segment profit growth across all five operating segments. The company currently trades at an 18x forward P/E with a market cap of $47.6 billion, below McKesson's 19x multiple, offering room for upside to the consensus 12-month target of $248.27. Strong operating cash flow of $686 million last quarter supports its buyback program and dividend yield of approximately 1%.
Conversely, the bear case notes Cardinal's razor-thin 1% operating margins and several near-term headwinds that could impact long-term returns. Key risks include an ongoing Department of Justice investigation into Anti-Kickback Statute violations, potential exposure to GMPD tariffs, and the danger of GLP-1 drugs becoming commoditized as they face greater competition. With earnings due on April 30 for Cardinal Health and May 6-7 for rivals like McKesson and CVS Health, investors will be watching closely to see if the specialty-led growth narrative validates William Blair's thesis. The recommendation aligns with a "Moderate Buy" consensus across 17 other analysts, though the company faces scrutiny from a regulatory and competitive landscape that remains complex.
💰 Cardinal Health posted 19% revenue growth and doubled cash flow last quarter.
🎯 Analysts rate shares "Outperform" based on a durable moat and specialty pivot.
🚀 Stock is a stealth compounder with 48% annualized returns over the past year.
⚖️ Management raised guidance to $10.35 EPS, trading at 18x forward earnings.
⚠️ Risks include razor-thin margins, regulatory investigations, and GLP-1 commoditization fears.
🏆 William Blair initiated coverage of Cardinal Health with an "Outperform" rating, highlighting its durable competitive moat and specialty-driven growth potential.
💰 The firm simultaneously launched an "Outperform" rating on rival McKesson, signaling strong conviction in the U.S. pharma distribution oligopoly.
📈 Cardinal Health generated 19% revenue growth to $65.63 billion last quarter, driven by a pivot toward higher-margin specialty services and GLP-1 drug volumes.
🎯 Stock performance reflects the "stealth compounder" thesis with 48% returns over the past year and 240% over five years.
💼 CEO Jason Hollar raised fiscal 2026 EPS guidance to $10.15–$10.35 and noted double-digit profit growth across all five operating segments.
🔗 Key strategic deals include the Solaris Health urology platform and Advanced Diabetes Supply partnerships to deepen the specialty mix.
⚖️ The company trades at 18x forward earnings, below McKesson's 19x, with a market cap of $47.6 billion and a consensus target of $248.27.
📅 William Blair's initiation was pre-earnings ahead of Cardinal Health's Q3 FY2026 results due on April 30, while competitors report in May.
💧 Operating cash flow surged 272% to $686 million last quarter, funding buybacks and the company's 1% dividend yield.
🐻 Bear case risks include razor-thin 1% operating margins, a DOJ Anti-Kickback Statute investigation, GLP-1 commoditization fears, and GMPD tariff exposure.
🤝 The current analyst consensus aligns with William Blair's upgrade, averaging a "Moderate Buy" across 17 Wall Street analysts.
🧬 Demographic tailwinds from an aging population alongside rising specialty medicine adoption are central to the long-term investment thesis.
Bullish Signals
William Blair initiates Outperform rating on Cardinal Health.
Revenue grew 19% YoY to $65.63 billion last quarter.
Beat EPS consensus at $2.63 non-GAAP per share.
CEO raised fiscal 2026 EPS guidance to $10.15-$10.35.
Operating cash flow surged 272% to $686 million.
Projected double-digit profit growth across all five segments.
Trades at attractive 18x forward earnings with upside.
Stock gained 48% this year and 240% over five years.
GLP-1 commoditization may compress future margins.
Bullish Signals
William Blair initiated coverage of Cardinal Health with an Outperform rating, signaling strong institutional confidence in the company's prospects.
The company delivered a robust 19% year-over-year revenue growth to $65.63 billion last quarter, demonstrating strong top-line momentum.
Cardinal Health beat analyst consensus on non-GAAP EPS at $2.63, validating its operational execution and profitability.
CEO Jason Hollar raised fiscal 2026 EPS guidance to a range of $10.15 to $10.35, reflecting increased management confidence in future earnings.
The company achieved a massive 272% surge in operating cash flow to $686 million last quarter, providing ample liquidity for share buybacks and dividends.
Segment profit growth is projected to remain at least double-digit across all five operating segments according to management.
Cardinal Health trades at an attractive valuation of 18x forward earnings with a significant upside potential from the consensus 12-month target price.
The stock has delivered impressive historical returns, gaining 48% over the past year and 240% over five years.
Risk Factors
Cardinal Health operates with razor-thin operating margins of just 1%, leaving little room for error or pricing power erosion.
The company faces significant regulatory overhang from an ongoing DOJ Anti-Kickback Statute investigation.
Potential exposure to GMPD (generic drug price transparency) tariffs poses a risk to profitability in the generics segment.
There is a downside risk that GLP-1 drugs could become commoditized, which may compress margins despite high volume growth.
The upcoming Q3 FY2026 earnings release on April 30 will be critical for validating whether the specialty-led growth narrative can truly offset these structural risks.
While William Blair initiated coverage at Outperform, Cardinal Health was notably excluded from an analyst's top 10 stocks list, indicating mixed expert opinion.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
